Cargando…

A randomized, phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, non-small cell lung cancer

BACKGROUND: Maintenance therapy for non-small cell lung cancer (NSCLC) aims to extend disease control after first-line chemotherapy with active and well-tolerated agents. The utility of continuation maintenance therapy requires further research. METHODS: This multicenter, randomized, phase 2 study c...

Descripción completa

Detalles Bibliográficos
Autores principales: Mubarak, Nabil, Gaafar, Rabab, Shehata, Samir, Hashem, Tarek, Abigeres, Dani, Azim, Hamdy A, El-Husseiny, Gamal, Al-Husaini, Hamed, Liu, Zhixin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477017/
https://www.ncbi.nlm.nih.gov/pubmed/23006447
http://dx.doi.org/10.1186/1471-2407-12-423
_version_ 1782247161761628160
author Mubarak, Nabil
Gaafar, Rabab
Shehata, Samir
Hashem, Tarek
Abigeres, Dani
Azim, Hamdy A
El-Husseiny, Gamal
Al-Husaini, Hamed
Liu, Zhixin
author_facet Mubarak, Nabil
Gaafar, Rabab
Shehata, Samir
Hashem, Tarek
Abigeres, Dani
Azim, Hamdy A
El-Husseiny, Gamal
Al-Husaini, Hamed
Liu, Zhixin
author_sort Mubarak, Nabil
collection PubMed
description BACKGROUND: Maintenance therapy for non-small cell lung cancer (NSCLC) aims to extend disease control after first-line chemotherapy with active and well-tolerated agents. The utility of continuation maintenance therapy requires further research. METHODS: This multicenter, randomized, phase 2 study compared continuation maintenance therapy with pemetrexed (500 mg/m(2) every 21 days) and best supportive care (BSC) versus BSC alone in patients with advanced, non-squamous NSCLC who had not progressed after 4 cycles of induction chemotherapy with pemetrexed (500 mg/m(2)) and cisplatin (75 mg/m(2)). The primary endpoint was progression-free survival (PFS) from randomization, was analyzed using a Cox model, stratified for the tumor response at the end of induction therapy, at a one-sided alpha of 0.2. Secondary endpoints: response and disease control rates, overall survival (OS), one year survival rates, and treatment-emergent adverse events (TEAEs). RESULTS: A total of 106 patients commenced induction therapy, of whom 55 patients were randomized to maintenance pemetrexed/BSC (n = 28) or BSC (n = 27). Although the median PFS time for maintenance phase for both arms was 3.2 months, the one-sided p-value for the PFS HR comparison was less than the prespecified limit of 0.2 (HR = 0.76, two-sided 95% confidence interval [CI]: 0.42 to 1.37; one-sided p-value = 0.1815), indicating that PFS was sufficiently long in the pemetrexed/BSC arm to warrant further investigation. Similar PFS results were observed for the overall study period (induction plus maintenance) and when the PFS analysis was adjusted for sex, baseline disease stage, and the ECOG PS prior to randomization. The median OS for the maintenance phase was 12.2 months (95%CI: 5.6 to 20.6) for the pemetrexed/BSC arm and 11.8 months (95% CI: 6.3 to 25.6) for BSC arm. The one-year survival probabilities were similar for both arms for the maintenance phase and the overall study period. Both the induction and continuation maintenance therapies were generally well-tolerated, and similar proportion of patients in each arm experienced at least 1 grade 3/4 TEAE (pemetrexed/BSC, 17.9%; BSC, 18.5%). CONCLUSIONS: Continuation pemetrexed maintenance therapy resulted in promising PFS with an acceptable safety profile in a Middle Eastern population with advanced non-squamous NSCLC and is worthy of further investigation. TRIAL REGISTRATION: NCT00606021
format Online
Article
Text
id pubmed-3477017
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-34770172012-10-20 A randomized, phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, non-small cell lung cancer Mubarak, Nabil Gaafar, Rabab Shehata, Samir Hashem, Tarek Abigeres, Dani Azim, Hamdy A El-Husseiny, Gamal Al-Husaini, Hamed Liu, Zhixin BMC Cancer Research Article BACKGROUND: Maintenance therapy for non-small cell lung cancer (NSCLC) aims to extend disease control after first-line chemotherapy with active and well-tolerated agents. The utility of continuation maintenance therapy requires further research. METHODS: This multicenter, randomized, phase 2 study compared continuation maintenance therapy with pemetrexed (500 mg/m(2) every 21 days) and best supportive care (BSC) versus BSC alone in patients with advanced, non-squamous NSCLC who had not progressed after 4 cycles of induction chemotherapy with pemetrexed (500 mg/m(2)) and cisplatin (75 mg/m(2)). The primary endpoint was progression-free survival (PFS) from randomization, was analyzed using a Cox model, stratified for the tumor response at the end of induction therapy, at a one-sided alpha of 0.2. Secondary endpoints: response and disease control rates, overall survival (OS), one year survival rates, and treatment-emergent adverse events (TEAEs). RESULTS: A total of 106 patients commenced induction therapy, of whom 55 patients were randomized to maintenance pemetrexed/BSC (n = 28) or BSC (n = 27). Although the median PFS time for maintenance phase for both arms was 3.2 months, the one-sided p-value for the PFS HR comparison was less than the prespecified limit of 0.2 (HR = 0.76, two-sided 95% confidence interval [CI]: 0.42 to 1.37; one-sided p-value = 0.1815), indicating that PFS was sufficiently long in the pemetrexed/BSC arm to warrant further investigation. Similar PFS results were observed for the overall study period (induction plus maintenance) and when the PFS analysis was adjusted for sex, baseline disease stage, and the ECOG PS prior to randomization. The median OS for the maintenance phase was 12.2 months (95%CI: 5.6 to 20.6) for the pemetrexed/BSC arm and 11.8 months (95% CI: 6.3 to 25.6) for BSC arm. The one-year survival probabilities were similar for both arms for the maintenance phase and the overall study period. Both the induction and continuation maintenance therapies were generally well-tolerated, and similar proportion of patients in each arm experienced at least 1 grade 3/4 TEAE (pemetrexed/BSC, 17.9%; BSC, 18.5%). CONCLUSIONS: Continuation pemetrexed maintenance therapy resulted in promising PFS with an acceptable safety profile in a Middle Eastern population with advanced non-squamous NSCLC and is worthy of further investigation. TRIAL REGISTRATION: NCT00606021 BioMed Central 2012-09-24 /pmc/articles/PMC3477017/ /pubmed/23006447 http://dx.doi.org/10.1186/1471-2407-12-423 Text en Copyright ©2012 Mubarak et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Mubarak, Nabil
Gaafar, Rabab
Shehata, Samir
Hashem, Tarek
Abigeres, Dani
Azim, Hamdy A
El-Husseiny, Gamal
Al-Husaini, Hamed
Liu, Zhixin
A randomized, phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, non-small cell lung cancer
title A randomized, phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, non-small cell lung cancer
title_full A randomized, phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, non-small cell lung cancer
title_fullStr A randomized, phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, non-small cell lung cancer
title_full_unstemmed A randomized, phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, non-small cell lung cancer
title_short A randomized, phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, non-small cell lung cancer
title_sort randomized, phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, non-small cell lung cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477017/
https://www.ncbi.nlm.nih.gov/pubmed/23006447
http://dx.doi.org/10.1186/1471-2407-12-423
work_keys_str_mv AT mubaraknabil arandomizedphase2studycomparingpemetrexedplusbestsupportivecareversusbestsupportivecareasmaintenancetherapyafterfirstlinetreatmentwithpemetrexedandcisplatinforadvancednonsquamousnonsmallcelllungcancer
AT gaafarrabab arandomizedphase2studycomparingpemetrexedplusbestsupportivecareversusbestsupportivecareasmaintenancetherapyafterfirstlinetreatmentwithpemetrexedandcisplatinforadvancednonsquamousnonsmallcelllungcancer
AT shehatasamir arandomizedphase2studycomparingpemetrexedplusbestsupportivecareversusbestsupportivecareasmaintenancetherapyafterfirstlinetreatmentwithpemetrexedandcisplatinforadvancednonsquamousnonsmallcelllungcancer
AT hashemtarek arandomizedphase2studycomparingpemetrexedplusbestsupportivecareversusbestsupportivecareasmaintenancetherapyafterfirstlinetreatmentwithpemetrexedandcisplatinforadvancednonsquamousnonsmallcelllungcancer
AT abigeresdani arandomizedphase2studycomparingpemetrexedplusbestsupportivecareversusbestsupportivecareasmaintenancetherapyafterfirstlinetreatmentwithpemetrexedandcisplatinforadvancednonsquamousnonsmallcelllungcancer
AT azimhamdya arandomizedphase2studycomparingpemetrexedplusbestsupportivecareversusbestsupportivecareasmaintenancetherapyafterfirstlinetreatmentwithpemetrexedandcisplatinforadvancednonsquamousnonsmallcelllungcancer
AT elhusseinygamal arandomizedphase2studycomparingpemetrexedplusbestsupportivecareversusbestsupportivecareasmaintenancetherapyafterfirstlinetreatmentwithpemetrexedandcisplatinforadvancednonsquamousnonsmallcelllungcancer
AT alhusainihamed arandomizedphase2studycomparingpemetrexedplusbestsupportivecareversusbestsupportivecareasmaintenancetherapyafterfirstlinetreatmentwithpemetrexedandcisplatinforadvancednonsquamousnonsmallcelllungcancer
AT liuzhixin arandomizedphase2studycomparingpemetrexedplusbestsupportivecareversusbestsupportivecareasmaintenancetherapyafterfirstlinetreatmentwithpemetrexedandcisplatinforadvancednonsquamousnonsmallcelllungcancer
AT mubaraknabil randomizedphase2studycomparingpemetrexedplusbestsupportivecareversusbestsupportivecareasmaintenancetherapyafterfirstlinetreatmentwithpemetrexedandcisplatinforadvancednonsquamousnonsmallcelllungcancer
AT gaafarrabab randomizedphase2studycomparingpemetrexedplusbestsupportivecareversusbestsupportivecareasmaintenancetherapyafterfirstlinetreatmentwithpemetrexedandcisplatinforadvancednonsquamousnonsmallcelllungcancer
AT shehatasamir randomizedphase2studycomparingpemetrexedplusbestsupportivecareversusbestsupportivecareasmaintenancetherapyafterfirstlinetreatmentwithpemetrexedandcisplatinforadvancednonsquamousnonsmallcelllungcancer
AT hashemtarek randomizedphase2studycomparingpemetrexedplusbestsupportivecareversusbestsupportivecareasmaintenancetherapyafterfirstlinetreatmentwithpemetrexedandcisplatinforadvancednonsquamousnonsmallcelllungcancer
AT abigeresdani randomizedphase2studycomparingpemetrexedplusbestsupportivecareversusbestsupportivecareasmaintenancetherapyafterfirstlinetreatmentwithpemetrexedandcisplatinforadvancednonsquamousnonsmallcelllungcancer
AT azimhamdya randomizedphase2studycomparingpemetrexedplusbestsupportivecareversusbestsupportivecareasmaintenancetherapyafterfirstlinetreatmentwithpemetrexedandcisplatinforadvancednonsquamousnonsmallcelllungcancer
AT elhusseinygamal randomizedphase2studycomparingpemetrexedplusbestsupportivecareversusbestsupportivecareasmaintenancetherapyafterfirstlinetreatmentwithpemetrexedandcisplatinforadvancednonsquamousnonsmallcelllungcancer
AT alhusainihamed randomizedphase2studycomparingpemetrexedplusbestsupportivecareversusbestsupportivecareasmaintenancetherapyafterfirstlinetreatmentwithpemetrexedandcisplatinforadvancednonsquamousnonsmallcelllungcancer
AT liuzhixin randomizedphase2studycomparingpemetrexedplusbestsupportivecareversusbestsupportivecareasmaintenancetherapyafterfirstlinetreatmentwithpemetrexedandcisplatinforadvancednonsquamousnonsmallcelllungcancer